



CIN NO.: L24230WB1982PLC034492

Date: 24th May, 2023

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Outcome of Board Meeting held on 24th May, 2023

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Director at its meeting was held on Wednesday, 24th May, 2023 (**commenced at 11:00 A.M. and concluded at 11:50 A.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Audited Financial Results of the Company for the 04th quarter and year ended 31st March, 2023 along with the Statement of Assets and Liabilities.
2. Audit Report by the Statutory Auditors on Standalone Audited Financial Results for 04th quarter and year ended 31st March, 2023.
3. Declaration by Whole-time Director pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 is enclosed herewith.
4. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.
5. M/s. Jain N. K. & Co. Chartered Accountant in practice is appointed as Internal Auditor of the Company for the Financial Year 2023-2024 pursuant to Section 138 of Companies Act 2013.
6. M/s. Veenit pal & Associates, Company Secretary in practice is appointed as Secretarial Auditors of the Company for Financial Year 2023-2024 pursuant to Section 204 of the Companies Act, 2013.

This information is also available on Company's website: www.adinathbio.com and on the stock exchange website: www.cse-india.com.

The Company would be publishing Extract of Audited Financial Result for the Quarter and year ended 31-03-2023, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Request you to kindly take the above on record.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

KISHAN Digitally signed
by KISHAN
SINGH
SINGH Date: 2023.05.24
11:55:17 +05'30'



Kishan Singh
(Whole-Time Director)
(DIN: 07526266)

Encl.: As above.

Adinath Bio-Labs Limited
CIN: L24230WB1982PLC034492

Statement of Standalone Audited Financial Results for the quarter and year ended 31st March, 2023

		PART I			(Rs. In lakhs)	
Sl. No.	Particulars	Quarter Ended			Year Ended	
		Audited (Refer note No. 4)	Unaudited	Audited (Refer note No. 4)	Audited	Audited
		31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
1	Income from operations					
	(a) Net Sales / income from operations	-	-	-	-	-
	(b) Other Income	-	-	4.051	8.491	5.319
	Total income from operations (net)	-	-	4.051	8.491	5.319
2	Expenses					
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-
	(b) Employee benefits expense	1.358	1.358	1.356	5.428	5.430
	(c) Finance Cost	-	-	-	-	-
	(d) Depreciation and amortisation expense	-	-	0.003	0.004	0.014
	(e) Other expenses	2.571	0.709	1.302	7.028	5.585
	Total expenses	3.929	2.067	2.661	12.460	11.029
3	Profit / (Loss) from operations before Exceptional & Extraordinary Items (1-2)	(3.929)	(2.067)	1.390	(3.969)	(5.710)
4	Exceptional & Extraordinary Items	-	-	-	-	99.915
5	Profit / (Loss) before Tax (3 ± 4)	(3.929)	(2.067)	1.390	(3.969)	(105.625)
6	Tax expense					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
	Earlier Years	-	-	-	-	-
	Total Tax Expenses	-	-	-	-	-
7	Net Profit/(Loss) after tax(5 ± 6)	(3.929)	(2.067)	1.390	(3.969)	(105.625)
8	Other Comprehensive Income / (Loss)	-	-	-	-	-
9	Total Comprehensive Income / (Loss) (7 ± 8)	(3.929)	(2.067)	1.390	(3.969)	(105.625)
10	Paid-up equity share capital	2,207.426	2,207.426	2,207.426	2,207.426	2,207.426
	(Face Value of the Share shall be indicated)(Re.)	1	1	1	1	1
11	Reserves excluding Revaluation Reserve				(2,210.613)	(2,206.644)
12	Earnings Per Share (not annualised except year ended):					
	Basic & Diluted	(0.002)	(0.001)	0.001	(0.002)	(0.048)

KISHAN SINGH Digitally signed
by KISHAN SINGH
Date: 2023.05.24
11:55:42 +05'30'



Notes:

- 1 The above Audited Financial results have been reviewed by the Audit committee at their meeting and adopted by the Board of Directors at their meeting held on 24th May, 2023.
- 2 The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The Company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The figures of the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures of the following financial year ended March 31, 2023 and March 31, 2022 and the published year to date unaudited figures upto nine months ended December 31, 2022 and December 31, 2021 respectively.
- 5 The accumulated losses of the company at the end of the financial year 2022-23 are more than fifty percent of its capital. However, having regard to restructuring exercise being implemented, the financial statements have been prepared on the basis that the Company is a going concern and that no adjustments are required to the carrying value of assets and liabilities.
- 6 Provisions for taxations is made on the taxable income for the full year in accordance with the provisions of Income Tax Act, 1961.
- 7 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

Date: 24th May, 2023

Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited

KISHAN SINGH Digitally signed
by KISHAN SINGH
Date: 2023.05.24
11:56:04 +05'30'

Kishan Singh
Whole - Time Director
DIN No.: 07526266

Statement of Audited Assets and Liabilities as on 31st March, 2023

(Rs. In lakhs)

Sl. No.	Particulars	As at 31st March, 2023	As at 31st March, 2022
I	ASSETS		
A	Non-current assets		
	a) Property, plant and equipment	0.983	0.987
	b) Financial assets		
	i) Investments	2.875	2.875
	ii) Other Non current financial assets	45.221	50.553
	Total Non-current assets	49.079	54.415
B	Current assets		
	a) Financial assets		
	i) Cash and cash equivalents	0.175	1.725
	ii) Loans and Advances	25.300	25.300
	iii) Other current financial assets	0.147	4.980
		-	-
	Total Current assets	25.622	32.005
	TOTAL ASSETS	74.701	86.420
II	EQUITY AND LIABILITIES		
A	EQUITY		
	a) Equity Share capital	2,207.426	2,207.426
	b) Other Equity	(2,210.613)	(2,206.644)
	Total equity	(3.187)	0.782
B	LIABILITIES		
I	Non-current liabilities		
	a) Financial liabilities		
	i) Borrowings	-	-
	ii) Other non-current financial liabilities	-	-
	(b) Long term provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	Total Non-current liabilities	-	-
II	Current liabilities		
	a) Financial liabilities		
	i) Borrowings	-	-
	ii) Trade payables	-	-
	iii) Other current financial liabilities	-	-
	b) Other current liabilities	1.275	1.165
	c) Current tax liabilities	76.613	84.473
	Total Current liabilities	77.888	85.638
	TOTAL EQUITY AND LIABILITIES	74.701	86.420

Date: 24th May, 2023
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited
KISHAN
SINGH

Digitally signed by KISHAN
SINGH
Date: 2023.05.24 11:56:26
+05'30'

Kishan Singh
Whole - Time Director
DIN No.: 07526266

CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH 2023		
(Rs. In lakhs)		
Particulars	For the Year Ended 31st March, 2023	For the Year Ended 31st March, 2022
(A) Cash Flow From Operating Activities		
Net Profit before Tax & Exceptional items	(3.969)	(5.710)
Adjustments for :-		
Profit on Sale of Fixed Assets	-	(2.789)
Other Income	(0.631)	(2.530)
Depreciation and Amortisation on tangible assets	0.004	0.014
Operating Profit Before Working Capital Changes	(4.596)	(11.015)
Adjustments for :-		
Working/ Operating Capital Changes		
(Increase)/ Decrease in Other Current Financial Assets	10.164	8.428
Increase/ (Decrease) in Other Current Liabilities	0.111	(1.506)
Cash Generated From Operations	5.679	(4.093)
Payment of Taxes	7.860	-
Net Cash Flow (Used in)/ Generated From Operating Activities (A)	(2.181)	(4.093)
(B) Cash Flow From Investing Activities		
Sales/ (Purchase) of Property, Plants and Equipments (Net)	-	3.250
Interest (Net)	0.631	2.530
Net Cash Flow (Used in)/ Generated From Investing Activities (B)	0.631	5.780
(C) Cash Flow From Financing Activities		
Net Cash Flow (Used in)/ Generated From Financing Activities (C)	-	-
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	(1.550)	1.687
Cash & Cash Equivalents as at the beginning of the year	1.725	0.038
Cash & Cash Equivalents as at the end of the year	0.175	1.725

Date: 24th May, 2023
Place: Kolkata



By order of the Board
For Adinath Bio-Labs Limited
KISHAN SINGH
Digitally signed by
KISHAN SINGH
Date: 2023.05.24
11:56:57 +05'30'
Kishan Singh
Whole - Time Director
DIN No.: 07526266

Independent Auditor's Report on Quarterly Standalone Financial Results and Standalone year to date Results of Adinath Bio-Labs Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To,
The Board of Directors of
Adinath Bio-Labs Limited**

We have audited the standalone financial results ('the Statement') of Adinath Bio-Labs Limited for the quarter and year ended March 31, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a. is presented in accordance with the requirements of the Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('IND AS'), and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended 31st March 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Financial Results

These standalone financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate



accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
4. Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the



appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decision of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31st March 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For KSA & Co.

Chartered Accountants

Firm registration No: 003822CCO.

Kamal Piyush

Kamal Piyush

Partner

Membership No: 083399

UDIN: 23083399BGXJ4Z9598

Place : New Delhi

Date : May 24, 2023



DECLARATION

[Pursuant to Regulation 33 (3) (d) of the

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016]

Dear Sir,

I, Kishan Singh (DIN: 07526266), Whole Time Director of Adinath Bio-labs Limited, hereby declared and confirmed that, the Statutory Auditors of the Company, M/s. KSA & Co., Chartered Accountant (FRN: 003822C) have issued an Audit Report with unmodified opinion on Annual Audited Standalone Financial Result for the quarter and year ended 31st March, 2023.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25/05/2016 and Circular No. CIR/CFD/CMD/56/2016 dated 27/05/2016.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

KISHAN Digitally signed
by KISHAN SINGH
SINGH Date: 2023.05.24
11:57:32 +05'30'

Kishan Singh
(Whole-Time Director)
(DIN: 07526266)



Date: 24th May 2023

Place: Kolkata

Date: 24th May, 2023

To,
The Secretary,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata – 700 001

Dear Sir,

Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 31st March, 2023.

You are requested to take the above information in your records.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

KISHAN Digitally signed
by KISHAN SINGH
Date: 2023.05.24
11:57:53 +05'30'

Kishan Singh
(Whole-Time Director)
DIN: 07526266

